查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
至2030年人類類器官市場預測：按產品、可用性、應用、最終用戶和地區進行的全球分析
市場調查報告書
商品編碼
1383372

至2030年人類類器官市場預測：按產品、可用性、應用、最終用戶和地區進行的全球分析

Human Organoids Market Forecasts to 2030 - Global Analysis By Product (Kidney, Colorectal, Liver, Pancreas, Heart and Other Products), Usabilty, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2023年全球人類類器官市場規模為 23.8 億美元，預計2030年將達到 80.4 億美元。

人類類器官是具有類似器官功能的大量人類細胞或組織。它是由人體幹細胞製成的3D系統。這使得以驚人的精度再現人體器官的結構和功能成為可能。除了動物模型之外，人類類器官為人類疾病的研究提供了豐富的機會。對遺傳異常、癌症、感染疾病等各種疾病的研究已經徹底改變。它也用於對人類幹細胞進行基因工程，並使用來自患者的切片檢查樣本而不是幹細胞來治療疾病。

根據世界衛生組織（WHO）的資料，截至2018年，北美地區GDP的16.416%用於醫療保健領域。

器官移植的進展

隨著人類類器官的引進，器官移植領域也取得了長足的進展。用於移植的器官可以從類器官中獲得，無需器官捐贈者。器官移植有助於解決與器官移植相關的道德難題，例如缺乏可用的捐贈者以及器官販運的道德影響。透過在植入前進行廣泛的測試和調整，可以降低這些風險並提高手術安全性和成功率。這些因素推動市場擴張。

缺乏熟練的專業人員

需要技術人員和研究人員等技術純熟勞工來推出、進行、記錄結果、收集資料和評估類器官研究。對基本科學概念理解不夠、選擇合適的方法不僅增加了研究人員和服務提供者的工作量和時間限制，而且還會產生各種直接和間接成本。因此，需要高素質的人員來進行解釋、方法開發、檢驗、操作和故障排除。這是市場拓展的障礙。

越來越重視替代方法的開發

醫學研究經常使用動物模型來研究人類特有的疾病。然而，有一些例子，例如藥物毒性研究，顯示動物模型不一定是人類藥物反應的可靠預測因子。這是因為人類的藥物代謝和毒物代謝與動物顯著不同，利用實驗小鼠等模型研究藥物代謝極為困難。儘管目前的重點是減少研究中動物的使用，但類器官有望推動市場成長，因為它們可以作為動物模型的可行替代品。

3D 細胞培養基礎設施不足

擁有採用尖端方法所需的工具是進行基於 3D 細胞培養的研究的要求之一。將類器官涵蓋目前的研究方法存在許多技術障礙，因為類器官的生產既耗時又耗資。此外，建立 3D 單元製造的基礎設施和設備需要大量成本和時間。這是阻礙市場拓展的因素。

COVID-19 的影響：

人類類器官市場受到 COVID-19 爆發的嚴重影響。在大流行期間，隨著疫苗上市的研發工作迅速增加，類器官的使用增加。類器官在大流行期間廣泛用於藥物研究的主要原因包括它們與真實器官的相似性、細胞向性、細胞活力和其他考慮因素。

在預測期內，發育生物學領域預計將是最大的。

在預測期內，發育生物學領域預計將是最大的。配子發生、受精、胚胎發育、成體發育和老化的過程都包含在發育生物學中。從培養的幹細胞和組織中創造類器官、架構是可能的。人類類器官培養提供了一個機會來研究人類發育並在使用非人類模型物種的研究中經常看到的詳細程度模擬疾病過程。

預計生技公司在預測期內的年複合成長率最高。

生技公司領域預計在預測期內年複合成長率最高。在藥物開發過程和隨後的監管備案過程中，這些公司需要提供與藥物開發相關的某些資料。遵守監管標準需要在早期開發和階段提供廣泛的服務。由於創造新的治療化合物相關的技術和監管障礙，製藥和生物技術公司面臨時間和成本的複雜問題。

佔有率最大的地區

由於有多家使用類器官 3D 培養技術的製藥和生物技術公司，與研究機構和臨床實驗室合作進行再生醫學和藥物研發發現開發，預計北美將在預測期內佔據最大的市場佔有率。每年較高的人均政府醫療支出，有利的政府政策，易於獲得的先進技術以及較高的採用率推動該地區人類類器官產業的擴張。

年複合成長率最高的地區：

由於經濟發展和較低的營運成本，預計亞太地區在預測期內將保持最高的年複合成長率。對生物製藥研究和開發的日益重視，藥品生產量的增加以及癌症發病率的上升推動該地區的市場擴張。此外，政府現代化法律和現行法規限制在藥物臨床試驗中使用動物試驗。因此，在整個臨床試驗和其他藥物開發過程中，採取不同的方法進行藥物測試。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計/預測/年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球人類類器官市場：依產品

  • 介紹
  • 腎
  • 大腸直腸
  • 肝
  • 胰臟
  • 心
  • 其他產品

第6章 全球人類類器官市場：依可用性分類

  • 介紹
  • 客製化產品
  • 即用型產品

第7章 全球人體器官市場：依應用分類

  • 介紹
  • 病理
  • 個人化醫療
  • 幹細胞研究
  • 再生醫學
  • 發育生物學

第8章 全球人類類器官市場：依最終使用者分類

  • 介紹
  • 學術研究所
  • 藥品
  • 生技公司
  • 醫院
  • 診斷中心
  • 其他最終用戶

第9章 全球人類類器官市場：依地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第10章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Hurel Corporation
  • BioIVT
  • Organovo
  • Kaly-Cell
  • HUB Organoids
  • Thermo Fisher Scientific
  • Kirkstall
  • InSphero
  • Corning Incorporated
  • Kerafast
  • ZenBio
  • CN Bio Innovations
  • Stemcell Technologies
  • Promethera Biosciences
  • Biopredic International
  • Cyfuse Biomedical
  • System1 Biosciences, Inc.
  • Mimetas
Product Code: SMRC24222

According to Stratistics MRC, the Global Human Organoids Market is accounted for $2.38 billion in 2023 and is expected to reach $8.04 billion by 2030 growing at a CAGR of 19% during the forecast period. Human organoids are developed masses of human cells or tissue that have an organ-like function. It's a three-dimensional system made of human stem cells. This has allowed for the remarkably accurate replication of the structure and functionality of human organs. Human organoids provide a wealth of opportunities for the study of human illness in addition to animal models. The study of different diseases, such as genetic abnormalities, cancer, and infectious diseases, has revolutionized. They are employed in the genetic engineering of human stem cells and, in lieu of stem cells, in the treatment of disease using biopsy samples from patients.

According to the World Health Organization (WHO), as of 2018, 16.416 % of the GDP was spent on the healthcare sector in North America.

Market Dynamics:

Driver:

Higher procedure of organ transplantation

The field of organ transplantation has advanced significantly with the introduction of human organoids, which may lead to improved protocols and results. Organs for transplantation can be obtained from organoids without the need for organ donors. They assist in resolving moral conundrums related to organ transplantation, such as the scarcity of available donors and the moral implications of organ trafficking. By enabling extensive testing and tuning before to transplantation, they reduce these hazards and enhance operation safety and success rates. These elements are enhancing the market's expansion.

Restraint:

Dearth of skilled professionals

It takes skilled workers, such technicians and researchers, to set up and conduct organoid studies, as well as to record findings, collect data, and evaluate it. Inadequate understanding of the fundamental scientific concepts and appropriate technique selection can lead to various direct and indirect costs, as well as increased workload and time constraints for researchers and service providers. Therefore, highly qualified workers are required for tasks like interpretation, method creation, validation, operation, and troubleshooting. This is the obstacle preventing the market from expanding.

Opportunity:

Growing focus on developing alternatives

In biomedical research, animal models are frequently utilized to study illnesses unique to humans. But there are several instances that show that, like with drug toxicity research, animal models are not necessarily reliable predictors of human drug response. This is due to the fact that human metabolism of medications and poisons differs greatly from that of animals, making it extremely difficult to investigate drug metabolism using experimental models such lab mouse species. The present focus on decreasing animal use in research is projected to assist the market's growth, since organoids can act as viable substitutes for animal models.

Threat:

Inadequate infrastructure for 3D cell culture

Having the tools needed to employ cutting-edge methods is one requirement for carrying out 3D cell culture-based research. The incorporation of organoids into current research processes presents a number of technical hurdles due to the capital- and time-intensive nature of organoid manufacture. Furthermore, it takes a significant amount of money and time to set up the infrastructure and equipment for 3D cell production. This is the element impeding the market's expansion.

COVID-19 Impact:

The human organoids market was impacted significantly by the COVID-19 epidemic. The increased use of organoids during the pandemic was caused by the rapid increase in research and development efforts for the vaccine's release. Some of the main reasons why organoids were widely used in medication research during the pandemic were their similarity to real organs, cell tropism, cell survival, and other considerations.

The developmental biology segment is expected to be the largest during the forecast period

The developmental biology segment is expected to be the largest during the forecast period. The processes of gamete formation, fertilization, embryonic development, adult organism emergence, and senescence are all included in developmental biology. It is possible to create organoids-structures that mimic the in vivo architecture and function of whole organs-from stem cells or tissues grown in culture. Human organoid cultures offer the opportunity to investigate human development and simulate illness processes at the same level of detail that is often associated with studies with nonhuman model species.

The biotechnology companies segment is expected to have the highest CAGR during the forecast period

The biotechnology companies segment is expected to have the highest CAGR during the forecast period. During the medication development process and the subsequent filing of applications to regulatory authorities, these businesses are required to provide particular data relating to drug development. In order to comply with regulatory standards, a broad range of services are required during the early development and clinical phases. Pharmaceutical and biotechnology businesses face time and expense complications as a result of the technical and regulatory obstacles associated with the creation of novel therapeutic compounds.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the presence of several pharmaceutical and biotechnology companies that use organoid 3D culture technology in collaboration with research institutes and clinical laboratories for developing regenerative medicines and drug discovery & development. The governments' large yearly per capita healthcare expenditures, together with favorable government policies and easy access to and high adoption of sophisticated technology, are propelling the expansion of the human organoids industry in this region.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to economic development and low operating costs. The increasing emphasis on biopharmaceutical R&D, massive medication manufacturing, and rise in cancer prevalence fuel the market's expansion in this area. Furthermore, the government's modernization act and current rules restrict the use of animal experimentation in medication clinical trials. As a result, throughout clinical trials and other drug development processes, a different approach to drug testing is adopted.

Key players in the market

Some of the key players in Human Organoids market include: Hurel Corporation, BioIVT, Organovo, Kaly-Cell, HUB Organoids , Thermo Fisher Scientific, Kirkstall, InSphero, Corning Incorporated, Kerafast , ZenBio , CN Bio Innovations, Stemcell Technologies, Promethera Biosciences, Biopredic International, Cyfuse Biomedical, System1 Biosciences, Inc. and Mimetas.

Key Developments:

In April 2023, InSphero AG announced that the company is making their patented Akura 96 and 384 Spheroid Microplates available to researchers in the Indian market by signing a distribution agreement with Bionova Supplies in biotechnology and scientific instruments.

In March 2023, Molecular Devices, LLC and HUB Organoids (HUB) announced a strategic collaboration enabling continued development of next-generation 3D biology technologies that drive step-change reduction in pre-clinical to clinical drug attrition.

In February 2023, Thermo Fisher Scientific and Celltrio collaborated to bring a fully automated cell culture system to biotherapeutics customers.

Products Covered:

  • Kidney
  • Colorectal
  • Liver
  • Pancreas
  • Heart
  • Other Products

Usabilty Covered:

  • Customizable Products
  • Ready to Use Products

Applications Covered:

  • Disease Pathology
  • Personalized Medicine
  • Stem Cell Research
  • Regenerative Medicine
  • Developmental Biology
  • Disease Biomarker Discovery:
  • Drug Toxicity & Efficacy Testing
  • Organ Transplantation
  • Cancer Research
  • Neurological Studies
  • Other Applications

End Users Covered:

  • Academic & Research Institutes
  • Pharmaceutical
  • Biotechnology Companies
  • Hospitals
  • Diagnostic Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Human Organoids Market, By Product

  • 5.1 Introduction
  • 5.2 Kidney
  • 5.3 Colorectal
  • 5.4 Liver
  • 5.5 Pancreas
  • 5.6 Heart
  • 5.7 Other Products

6 Global Human Organoids Market, By Usabilty

  • 6.1 Introduction
  • 6.2 Customizable Products
  • 6.3 Ready to Use Products

7 Global Human Organoids Market, By Application

  • 7.1 Introduction
  • 7.2 Disease Pathology
  • 7.3 Personalized Medicine
  • 7.4 Stem Cell Research
  • 7.5 Regenerative Medicine
  • 7.6 Developmental Biology

7.7 Disease Biomarker Discovery:

  • 7.8 Drug Toxicity & Efficacy Testing
  • 7.9 Organ Transplantation
  • 7.10 Cancer Research
  • 7.11 Neurological Studies
  • 7.12 Other Applications

8 Global Human Organoids Market, By End User

  • 8.1 Introduction
  • 8.2 Academic & Research Institutes
  • 8.3 Pharmaceutical
  • 8.4 Biotechnology Companies
  • 8.5 Hospitals
  • 8.6 Diagnostic Centers
  • 8.7 Other End Users

9 Global Human Organoids Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Hurel Corporation
  • 11.2 BioIVT
  • 11.3 Organovo
  • 11.4 Kaly-Cell
  • 11.5 HUB Organoids
  • 11.6 Thermo Fisher Scientific
  • 11.7 Kirkstall
  • 11.8 InSphero
  • 11.9 Corning Incorporated
  • 11.10 Kerafast
  • 11.11 ZenBio
  • 11.12 CN Bio Innovations
  • 11.13 Stemcell Technologies
  • 11.14 Promethera Biosciences
  • 11.15 Biopredic International
  • 11.16 Cyfuse Biomedical
  • 11.17 System1 Biosciences, Inc.
  • 11.18 Mimetas

List of Tables

  • Table 1 Global Human Organoids Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Human Organoids Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Human Organoids Market Outlook, By Kidney (2021-2030) ($MN)
  • Table 4 Global Human Organoids Market Outlook, By Colorectal (2021-2030) ($MN)
  • Table 5 Global Human Organoids Market Outlook, By Liver (2021-2030) ($MN)
  • Table 6 Global Human Organoids Market Outlook, By Pancreas (2021-2030) ($MN)
  • Table 7 Global Human Organoids Market Outlook, By Heart (2021-2030) ($MN)
  • Table 8 Global Human Organoids Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 9 Global Human Organoids Market Outlook, By Usabilty (2021-2030) ($MN)
  • Table 10 Global Human Organoids Market Outlook, By Customizable Products (2021-2030) ($MN)
  • Table 11 Global Human Organoids Market Outlook, By Ready to Use Products (2021-2030) ($MN)
  • Table 12 Global Human Organoids Market Outlook, By Application (2021-2030) ($MN)
  • Table 13 Global Human Organoids Market Outlook, By Disease Pathology (2021-2030) ($MN)
  • Table 14 Global Human Organoids Market Outlook, By Personalized Medicine (2021-2030) ($MN)
  • Table 15 Global Human Organoids Market Outlook, By Stem Cell Research (2021-2030) ($MN)
  • Table 16 Global Human Organoids Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 17 Global Human Organoids Market Outlook, By Developmental Biology (2021-2030) ($MN)
  • Table 18 Global Human Organoids Market Outlook, By Disease Biomarker Discovery: (2021-2030) ($MN)
  • Table 19 Global Human Organoids Market Outlook, By Drug Toxicity & Efficacy Testing (2021-2030) ($MN)
  • Table 20 Global Human Organoids Market Outlook, By Organ Transplantation (2021-2030) ($MN)
  • Table 21 Global Human Organoids Market Outlook, By Cancer Research (2021-2030) ($MN)
  • Table 22 Global Human Organoids Market Outlook, By Neurological Studies (2021-2030) ($MN)
  • Table 23 Global Human Organoids Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 24 Global Human Organoids Market Outlook, By End User (2021-2030) ($MN)
  • Table 25 Global Human Organoids Market Outlook, By Academic & Research Institutes (2021-2030) ($MN)
  • Table 26 Global Human Organoids Market Outlook, By Pharmaceutical (2021-2030) ($MN)
  • Table 27 Global Human Organoids Market Outlook, By Biotechnology Companies (2021-2030) ($MN)
  • Table 28 Global Human Organoids Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 29 Global Human Organoids Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 30 Global Human Organoids Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.